Systemic anti-tumor immune response

Systemic anti-tumor immune response" is not a specific molecule or receptor, but rather describes the coordinated activity of the body's immune system to recognize and destroy cancer cells throughout the body. This process involves multiple components of both innate and adaptive immunity, including CD8+ T cells (cytotoxic T lymphocytes), natural killer (NK) cells, macrophages (with M1/M2 phenotypes), myeloid-derived suppressor cells (MDSCs), dendritic cells, and regulatory T cells[1][2]. The effectiveness of this systemic response can be influenced by factors such as age, metabolic state, and the immunosuppressive nature of the tumor microenvironment[1]. Therapeutic strategies in cancer immunotherapy aim to enhance this systemic anti-tumor immunity by activating effector immune cells or inhibiting suppressive mechanisms within tumors[2]. However, "systemic anti-tumor immune response" itself is not a druggable target like a receptor or enzyme; it is a complex physiological process involving many molecular targets. Note: This entry does not correspond to an individual therapeutic target but rather an overall biological phenomenon. Therefore, - is_target should be set to false. - is_incorrect should be set to true because it does not refer to a single molecule/receptor suitable for structured drug-target information.

Other names

systemic antitumor immune responsesystemic anti-tumor immunitysystemic cancer immune response